Development of Replication-Defective HIV as Vaccine Candidate

Award Notice Posted

Solicitation number
75N93022C00013
Agency
Awarded
to Genecure LLC
Set-aside
Total Small Business

Opportunity facts

Contract number
75N93022C00013 Federal contract award
Place of performance
Norcross, Georgia 30071, United States

Notice details come from SAM.gov. Updated .

About this opportunity

Written by GovTribe AI ·

Genecure LLC was awarded a $300,000 contract by the National Institute of Allergy and Infectious Diseases to develop a replication-defective HIV vaccine candidate over the coming year. The contract, awarded on July 1, 2022 as a total small business set aside under number 75N93022C00013, will support Genecure's work advancing a vaccine aimed at addressing the ongoing HIV/AIDS crisis.

Notice text

Awarded contract 75N93022C00013 to Genecure LLC for 300000.00 on 2022-07-01.

Notice history

Notice Type Posted
VesiVax® HIVgp41e Vaccine Design Latest Award Notice
This notice Award Notice
An Integrated Multiplexed Electrochemical Platform for the Selective Detection of Viral Protein and RNA to Differentiate Active HIV-1 Infection from Vaccine Induced Seropositivity Award Notice
The IRIS-HIV Assay, a Point-of-Care, Multiplex Serological Assay to Identify HIV Infection and Vaccine-Induced Seropositivity Award Notice
A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Latest solicitation Solicitation
A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Original Pre-Solicitation

6 of 8 notices listed here. See the rest on GovTribe.

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity
Try for free Login

GovTribe for Federal Contractors